Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

HM15275

MARKETED

GLP-1/GIP/glucagon triple receptor agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

HM15275 is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
HM15275 MARKETED
Weight change Decrease
Very low evidence

HM15275 (Hanmi) is a once-weekly long-acting GLP-1/GIP/glucagon triple agonist engineered for obesity, designed to optimise receptor-activity balance to deliver weight...

Hanmi Pharmaceutical, ADA 2025 poster 774-P and ObesityWeek 2025 / company press Source
Full findingHM15275 (Hanmi) is a once-weekly long-acting GLP-1/GIP/glucagon triple agonist engineered for obesity, designed to optimise receptor-activity balance to deliver weight loss while minimising lean-mass loss. Phase 1 reported favourable safety and early weight loss; FDA-cleared for phase 2, which is under way.
PopulationPhase 1: adults, ~4-week early readout, safety/PK/PD. Phase 2 initiated H2 2025. Preclinical efficacy in rodent obesity models.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsanimal data; human relevance uncertain
Comparatorsplacebo